Targeting fetal hemoglobin expression to treat β hemoglobinopathies

References

• Steinberg MH, Forget BG, Higgs DR, et al., (editors). Disorders of hemoglobin: genetics, pathophysiology, clinical management.2nd. Cambridge University Press: Cambridge; 2009. p. 826.
   Google Scholar
• Gladwin MT, Kato GJ, Novelli EM, editor. Sickle cell disease. McGraw Hill. 2021. p.692
   Google Scholar
• Weatherall DJ, Clegg JB, eds. The thalassaemia syndromes. 4th ed. Wiley-Blackwell; 2008. p. 864.
   Google Scholar
• Leonova JY, Kazanetz EG, Smetanina NS, et al. Variability in the fetal hemoglobin level of the normal adult. Am J Hematol. 1996;53(2):59–65.
   PubMed Web of Science ®Google Scholar
• Lin J, Ye Y, Shang X, et al. TEA domain transcription factor 4 modulates repression of fetal haemoglobin by direct binding to the γ-globin gene promoters. Br J Haematol. 2021;195(5):764–769.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood. 2020 Nov 19;136(21):2392–2400.
   PubMed Web of Science ®Google Scholar
• Akinsheye I, Alsultan A, Solovieff N, et al., Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes. J Clin Med. 2020;9(11):3782.
   Web of Science ®Google Scholar
• Wienert B, Martyn GE, Funnell APW, et al. Wake-up sleepy gene: reactivating fetal globin for beta-hemoglobinopathies. Trends Genet. 2018;34(12):927–940.
   PubMed Web of Science ®Google Scholar
• Yu L, Myers G, Engel JD. Small molecule therapeutics to treat the β-globinopathies. Curr Opin Hematol. 2020;27(3):129–140.
   PubMed Web of Science ®Google Scholar
• Shen Y, Verboon JM, Zhang Y, et al. A unified model of human hemoglobin switching through single-cell genome editing. Nat Commun. 2021;12(1):4991.
   PubMed Web of Science ®Google Scholar
• Xu J, Bauer DR, Kerenyi MA, et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci USA. 2013;110(16):6518–6523.
   PubMed Web of Science ®Google Scholar
• Orkin SH. Molecular Medicine: found in translation. Med (NY). 2021;2:122–136.
   Google Scholar
• Liu N, Hargreaves VV, Zhu Q, et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. Cell. 2018;173(2):430–442.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. N Engl J Med. 2011;365(9):807–814.
   PubMed Web of Science ®Google Scholar
• Menzel S, Garner C, Gut I, et al., A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197–1199.
   PubMed Web of Science ®Google Scholar
• Sedgewick A, Timofeev N, Sebastiani P, et al. BCL11A (2p16) is a major HbF quantitative trait locus in three different populations. Blood Cells Mol Dis. 2008;41(3):255–258.
   PubMed Web of Science ®Google Scholar
• Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620–1625.
   PubMed Web of Science ®Google Scholar
• Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β- globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA. 2008;105(33):11869–11874.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839–1842.
   PubMed Web of Science ®Google Scholar
• Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 2011;334(6058):993–996.
   PubMed Web of Science ®Google Scholar
• Masuda T, Wang X, Maeda M, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science. 2016;351(6270):285–289.
   PubMed Web of Science ®Google Scholar
• Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342(6155):253–257.
   PubMed Web of Science ®Google Scholar
• Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015;527(7577):192–197.
   PubMed Web of Science ®Google Scholar
• Liu N, Xu S, Yao Q, et al. Transcription factor competition at the γ-globin promoters controls hemoglobin switching. Nat Genet. 2021;53(4):511–520.
   PubMed Web of Science ®Google Scholar
• Traxler EA, Yao Y, Wang, et al. Editing a 13 bp sequence in the HBG promoters. a genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016;22(9):987–990.
   PubMed Web of Science ®Google Scholar
• Frangoul H, Altshuler D, Cappellini MD, et al., CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260.
   PubMed Web of Science ®Google Scholar
• Esrick EB, Lehmann LE, Biffi A, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. 2021;384(3):205–215.
   PubMed Web of Science ®Google Scholar
• Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci USA. 1974;71(12):4864–4868.
   PubMed Web of Science ®Google Scholar
• Schechter AN, Noguchi CT. Sickle hemoglobin polymerization: structure-function correlates, in, sickle cell disease: basic principles and clinical practice. Embury SH, Hebbel RP, Mohandas N, et al., eds. Raven: NY; 1994. p. 902.
   Google Scholar
• Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA. 1979;76(2):670–672.
   PubMed Web of Science ®Google Scholar
• Bookchin RM, Balazs T, Nagel RL, et al. Polymerisation of haemoglobin SA hybrid tetramers. Nature. 1977;269(5628):526–527.
   PubMed Web of Science ®Google Scholar
• Khandros E, Blobel GA. Heterogeneity of fetal hemoglobin production in adult red blood cells. Curr Opin Hematol. 2021;28(3):164–170.
   PubMed Web of Science ®Google Scholar
• Khandros E, Huang P, Peslak SA, et al. Isolated changes in chromatin accessibility and enhancer-promoter contacts at the β-globin locus distinguish fetal hemoglobin producing F-cells from A-cells. Blood. 2021;138(Supplement 1):855. https://ash.confex.com/ash/2021/webprogram/Paper149877.html,855
   Google Scholar
• Dover GJ, Boyer SH. Fetal hemoglobin-containing cells have the same mean corpuscular hemoglobin as cells without fetal hemoglobin: a reciprocal relationship between gamma- and beta-globin gene expression in normal subjects and in those with high fetal hemoglobin production. Blood. 1987;69(4):1109–1113.
   PubMed Web of Science ®Google Scholar
• Dover GJ, Boyer SH, Charache S, et al. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med. 1978;299(26):1428–1435.
   PubMed Web of Science ®Google Scholar
• Boyer S, Belding T, Margolet L, et al. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science. 1975;188(4186):361–363.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Chui DH, Dover GJ, et al. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014 23; 123(4):481–485. and references therein.
   PubMed Web of Science ®Google Scholar
• Hebert N, Rakotoson MG, Bodivit G, et al. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. Am J Hematol. 2020;95(11):1235–1245.
   PubMed Web of Science ®Google Scholar
• Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006;108(3):1073–1076.
   PubMed Web of Science ®Google Scholar
• Prus E, Fibach E. Heterogeneity of F-cells in β-thalassemia. Transfusion. 2013;53(3):499–504.
   PubMed Web of Science ®Google Scholar
• Vathipadiekal V, Alsultan A, Baltrusaitis K, et al. Homozygosity for a haplotype in the HBG2-OR51B4 region is exclusive to Arab-Indian haplotype sickle cell anemia. Am J Hematol. 2016;9(6):E308–E311.
   Google Scholar
• Al-Ali AK, Alsulaiman A, Alzahrani AJ, et al. Prevalence and diversity of haplotypes of sickle cell disease in the Eastern province of Saudi Arabia. Hemoglobin. 2020;44(2):78–81.
   PubMed Web of Science ®Google Scholar
• Shaikho EM, Farrell JJ, Alsultan A, et al. Genetic determinants of HbF in Saudi Arabian and African Benin haplotype sickle cell anemia. Am J Hematol. 2017;92(9):E555–E557.
   PubMed Web of Science ®Google Scholar
• Vathipadiekal V, Farrell JJ, Wang S, et al. A candidate transacting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia. Am J Hematol. 2016;91(11):1118–1122.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89(3):1078–1088.
   PubMed Web of Science ®Google Scholar
• https://imagebank.hematology.org/image/3061/hemoglobin-shpfh.
   Google Scholar
• Hoyer JD, Penz CS, Fairbanks VF, et al. Flow cytometric measurement of hemoglobin F in RBCs: diagnostic usefulness in the distinction of hereditary persistence of fetal hemoglobin (HPFH) and hemoglobin S-HPFH from other conditions with elevated levels of hemoglobin F. Am J Clin Pathol. 2002;117(6):857–863.
   PubMed Web of Science ®Google Scholar
• Ngo DA, Aygun B, Akinsheye I, et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol. 2012;156(2):259–264.
   PubMed Web of Science ®Google Scholar
• Alsultan A, Alabdulaali MK, Griffin PJ, et al. Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign. Br J Haematol. 2014;164(4):597–604.
   PubMed Web of Science ®Google Scholar
• Akinsheye I, Solovieff N, Ngo D, et al. Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. Am J Hematol. 2012;87(2):217–219.
   PubMed Web of Science ®Google Scholar
• Hariharan P, Kishnani P, Sawant P, et al. Genotypic-phenotypic heterogeneity of delta beta-thalassemia and hereditary persistence of fetal hemoglobin (HPFH) in India. Ann Hematol. 2020;99(7):1475–1483.
   PubMed Web of Science ®Google Scholar
• Perrine RP, Pembrey ME, John P, et al. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med. 1978;88(1):1–6.
   PubMed Web of Science ®Google Scholar
• Perrine RP, John P, Pembrey M, et al. Sickle cell disease in Saudi Arabs in early childhood. Arch Dis Child. 1981;56(3):187–192.
   PubMed Web of Science ®Google Scholar
• Henry ER, Cellmer T, Dunkelberger EB, et al. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Proc Natl Acad Sci USA. 2020;117(26):15018–15027.
   PubMed Web of Science ®Google Scholar
• Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian prospective study on sickle cell disease. Blood. 1994;84(9):3182–3188.
   PubMed Web of Science ®Google Scholar
• Horiuchi K, Osterhout ML, Kamma H, et al. Estimation of fetal hemoglobin levels in individual red cells via fluorescence image cytometry. Cytometry1995. 1995;20(3):261–267.
   PubMedGoogle Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine (Baltimore). 1996;75(6):300–326.
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672.
   PubMed Web of Science ®Google Scholar
• McGann PT, Niss O, Dong M, et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. Am J Hematol. 2019;94(8):871–879.
   PubMed Web of Science ®Google Scholar
• Khandros E, Huang P, Peslak SA, et al. Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts. Blood. 2020;135(22):1957–1968.
   PubMed Web of Science ®Google Scholar
• Dulmovits BM, Appiah-Kubi AO, Papoin J, et al. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood. 2016;127(11):1481–1492.
   PubMed Web of Science ®Google Scholar
• Le CQ, Myers G, Habara A, et al. Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. Blood. 2019;133(22):2455–2459.
   PubMed Web of Science ®Google Scholar
• Sun Y, Habara A, Le CQ, et al. Pharmacologic induction of PGC −1α stimulates fetal haemoglobin gene expression. Br J Haematol. 2022;197(1):97–109.
   PubMed Web of Science ®Google Scholar
• Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 2017;14(9):e1002382.
   PubMed Web of Science ®Google Scholar
• Renneville A, Van Galen P, Canver MC. Canver MC, et al.EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015;126(16):1930–1939.
   PubMed Web of Science ®Google Scholar
• Charnigo RJ, Beidler D, Rybin D, et al. PF −04447943, a Phosphodiesterase 9A inhibitor, in stable sickle cell disease patients: a phase ib randomized, placebo-controlled study. Clin Transl Sci. 2019;12(2):180–188.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy S, Pace B, Gupta D, et al. Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell disease. JCI Insight. 2017;2(20). pii: 96409. https://doi.org/10.1172/jci.insight.96409.
   Google Scholar
• Dai Y, Shaikho EM, Perez J, et al. BCL2L1 is associated with γ-globin gene expression. Blood Adv. 2019;3(20):2995–3001.
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen T, Ijaz H, et al. SIRT1 activates the expression of fetal hemoglobin genes. Am J Hematol. 2017;92(11):1177–1186.
   PubMed Web of Science ®Google Scholar
• Yu X, Azzo A, Bilinovich SM, et al. Disruption of the MBD2-NuRD complex but not MBD3-NuRD induces high level HbF expression in human adult erythroid cells. Haematologica. 2019;104(12):2361–2371.
   PubMed Web of Science ®Google Scholar
• Peslak SA, Khandros E, Huang P, et al. Protein phosphatase 6c (PPP6C) loss significantly raises fetal hemoglobin levels and reduces cell sickling. Blood. 2021;138(Supplement 1):2031.
   PubMedGoogle Scholar
• Nataraja S, Singh M, Demes S, et al. A Novel BACH1 inhibitor that Induces fetal hemoglobin in treatment of sickle cell disease. Blood. 2021;138(Supplement 1):854.
   Google Scholar
• Li X, Chen M, Liu B, et al. Transcriptional silencing of fetal hemoglobin expression by NonO. Nucl Acids Res. 2021;49(17):9711–9723.
   PubMed Web of Science ®Google Scholar
• Grevet JD, Lan X, Hamagami N, et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science. 2018;36(6399):285–290.
   Google Scholar
• Huang P, Peslak SA, Lan X, et al. The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression. Blood. 2020;135(24):2121–2132.
   PubMed Web of Science ®Google Scholar
• Lan X, Ren R, Feng R, et al. ZNF410 uniquely activates the NuRD component CHD4 to silence fetal hemoglobin expression. Mol Cell. 2021;81(2):1032–1033.
   Web of Science ®Google Scholar
• Vinjamur DS, Yao Q, Cole MA, et al. ZNF410 represses fetal globin by singular control of CHD4. Nat Genet. 2021;53:719–728.
   PubMed Web of Science ®Google Scholar
• Matson D, Xie K, Roth M, et al. Ftx-6058 induces fetal hemoglobin production and ameliorates disease pathology in sickle mice. Blood. 2021;138(Supplement 1):2018.
   PubMedGoogle Scholar
• Lan X, Khandros E, Huang P, et al. The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells. Blood Adv. 2019;3(10):1586–1597.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion Independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467(7313):318–322.
   PubMed Web of Science ®Google Scholar
• Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479–1493.
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855.
   PubMed Web of Science ®Google Scholar
• Yannaki E, Locatelli F, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent β-thalassemia: updated long-term efficacy and safety results/. HemaSphere. 2021;5(S2). https://doi.org/10.1097/HS9.0000000000000487.
   Google Scholar
• Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-β0/β0 genotype β-thalassemia. N Engl J Med.2021 Dec 11. https://doi.org/10.1056/NEJMoa2113206. *Longer. *Longerterm effects of additive gene therapy in β thalassemia.
   Google Scholar
• Kanter J, Walters MC, Krishnamurti L, et al., Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386(7):617–628.
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Thompson AA, Mapara MY, et al. Polyclonality strongly correlates with biological outcomes and is significantly increased following improvements to the phase 1/2 Hgb-206 protocol and. manufacturing of lentiglobin for sickle cell disease (SCD: bb1111) gene therapy (GT). Blood. 2021;138(Supplement 1):561.
   Google Scholar
• Hsieh MM, Bonner M, Pierciey FJ, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020;4:2058–2063.
   PubMed Web of Science ®Google Scholar
• Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl Med. 2021. https://doi.org/10.1056/NEJMoa2109167.
   Google Scholar
• Grimley G, Asnani M, Shrestha A, et al. Safety and efficacy of Aru-1801 in patients with sickle cell disease: early results from the phase 1/2 momentum study of a modified gamma globin gene therapy and reduced intensity conditioning. Blood. 2021;138(Supplement 1).
   Google Scholar
• Brendel C, Guda S, Renella R, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest. 2016;126(10):3868–3878.
   PubMed Web of Science ®Google Scholar
• Di Caprio G, Schonbrun E, Gonçalves BP, et al. High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension. Proc Natl Acad Sci USA. 2019;116(50):25236–25242.
   PubMed Web of Science ®Google Scholar
• De Souza DC, Esrick EB, Hebert N, et al. Effects of BCL11A shmir-induced post-transcriptional silencing on hemoglobin polymer inhibition in single red blood cells at physiologic oxygen tension. Blood. 2021;138(Supplement 1):964.
   Google Scholar
• Grupp S, Bloberger N, Campbell G, et al. CTX001 for sickle cell disease: safety and efficacy results from the ongoing Climb SCD-121 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells. HemaSphere. 2021;5:S2 365.
   Google Scholar
• Locatelli F, Ailinca-Lucher S, Bobruf Y, et al. CTX001 for transfusion-dependent β thalassemia: safety and efficacy results from the ongoing Climb thal-111 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells. HemaSphere. 2021;5(S2):335.
   Google Scholar
• Alavi A, Krishnamurti L, Abedi M, et al. Preliminary safety and efficacy results from precizn-1: an ongoing phase 1/2 study on zinc finger nuclease-modified autologous CD34+ hspcs for sickle cell disease (scd). Blood. 2021;138(Supplement 1):2930.
   Google Scholar
• Cheng L, Li Y, Qi Q, et al. Single-nucleotide-level mapping of DNA regulatory elements that control fetal hemoglobin expression. Nat Genet. 2021;63(6):869–880.
   Google Scholar
• Antoniou P, Hardouin G, Matinucci P. Base editing-mediated dissection of the −200 region of the γ-globin promoters to induce fetal hemoglobin and rescue sickle cell disease and β-thalassemia. Blood. 2021;138(Supplement 1):562.
   Google Scholar
• Topfer SK, Feng R, Huang P, et al. Disrupting the adult-globin promoter alleviates promoter competition and reactivates fetal-globin gene expression. Blood. 2022;2021014205. Jan 28;blood. https://doi.org/10.1182/blood.2021014205.
   Google Scholar
• Han Y, Tan X, Jin T, et al. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression. Eur J Pharmacol. 2022;918:174788.
   PubMed Web of Science ®Google Scholar
• Cull A, Chapman MS, Cuculescu M, et al. Clonal tracking by whole genome sequencing permits comprehensive mapping of the genome landscape in pre- and post-gene therapy sickle cell patients. Blood. 2021;138(Supplement 1):559.
   Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383–1389.
   PubMed Web of Science ®Google Scholar
• Charache S, Conley CL. Conley CL Hereditary persistence of fetal hemoglobin. Ann NY Acad Sci. 1969;165(1 Second Confer):37–41.
   PubMedGoogle Scholar
• Maeda JS, Prasad K, Howard RJ, et al. Management of pregnancy when maternal blood has a very high level of fetal haemoglobin. Br J Haematol. 1994;88(2):432–434.
   PubMed Web of Science ®Google Scholar
• Ortner A, Zech H, Humpeler E, et al. May high oxygen affinity of maternal hemoglobin cause fetal growth retardation? Arch Gynecol. 1983;234:79–85.
   PubMedGoogle Scholar
• Brown EG, Mendoza GJ, Chervenak FA, et al. The relationship of maternal erythrocyte oxygen transport parameters to intrauterine growth retardation. Am J Obstet Gynecol. 1990;162(1):223–229.
   PubMed Web of Science ®Google Scholar
• Mendoza GJ, Brown EG, Calem-Grunat J, et al. Intrauterine growth retardation related to maternal erythrocyte oxygen transport Adv Exp Med Biol. 1989;(248):377–386.
   PubMedGoogle Scholar
• Henry ER, Metaferia B, Li Q, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 2021;138(13):1172–1181.
   PubMed Web of Science ®Google Scholar
• Rangat N, Oliveira JL, Hoyer JD, et al. High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: clinical outcomes and impact of therapy in 41 cases. Am J Hematol. 2021;96(12):1647–1654.
   PubMed Web of Science ®Google Scholar
• Charache S, Catalano P, Burns S, et al. Pregnancy in carriers of high-affinity hemoglobins. Blood. 1985;65:713–718.
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Eaton JW, Kronenberg RS, et al. Human llamas: adaptation to altitude in subjects with high hemoglobin oxygen affinity. J Clin Invest. 1978;62(3):593–600.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012;87(8):795–803.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37–47.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750–760.
   PubMed Web of Science ®Google Scholar
• Lattanzi A, Camarena J, Lahiri P, et al. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Trans Med. 2021;13(598):eabf2444.
   PubMed Web of Science ®Google Scholar
• Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;6(11):e585–e596.
   PubMed Web of Science ®Google Scholar
• Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142–151.
   PubMed Web of Science ®Google Scholar
• Porcu S, Simbula M, Marongiu MF, et al. Delta-globin gene expression improves sickle cell disease in a humanized mouse model. Br J Haematol. 2021;193(6):1228–1237.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. HbA 2 induction: the merit of pancellularity in sickle cell disease. Br J Haematol. 2021;193(6):1032–1033.
   PubMed Web of Science ®Google Scholar